Kineta CEO Unveils its Immuno-oncology Program at the BIO Investor Forum
Presentation focused on novel treatment strategies
Seattle, WA, October 19, 2016 – Kineta, Inc., a biotechnology company focused on the translational development of novel antiviral and immune modulating therapies announced that its CEO, Dr. Shawn Iadonato, joined a panel of leaders from other biopharmaceutical companies to discuss novel new treatment strategies in immuno-oncology. The panel presentation entitled "The Intersection of Inflammation and Immuno-Oncology: Risks and Opportunities" was conducted at the 15th annual BIO Investor Forum in San Francisco.
Dr. Iadonato highlighted details around Kineta’s small molecule compounds that may activate the RIG-I pathway to elicit immunogenic cell death in cancer tumor models. These novel compounds were identified using Kineta’s proprietary AVIiD™ screening platform which has also identified innate immune antivirals and vaccine adjuvants. "Cancer is typically not recognized as foreign by the body’s immune system which allows tumors to grow unchecked", stated Kineta CEO Dr. Shawn Iadonato. "Kineta’s immune modulators activate the RIG-I pathway and may reprogram the immune system to recognize tumors as foreign and elicit neo-antigen T-cell responses to kill cancer. Priming the tumor microenvironment may also enable other therapies to be more effective when used in combination."
The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-One Partnering™ meetings
Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in chronic pain, immuno-oncology and infectious diseases. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. For more information on Kineta, Inc. visit our website, www.Kinetabio.com
NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, anticipated drug effects in human subjects, and financial performance. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation: progress of drug development; ability to raise capital to fund drug development; clinical testing and regulatory approval; intellectual property protection and enforcement; our ability to recruit and retain scientists and other key personnel; competition from other drug development companies; and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.